SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: JohnP who wrote (783)9/21/1998 8:32:00 PM
From: Biomaven  Read Replies (1) | Respond to of 965
 
My guess is that it is a combination of the biotech rally we've seen in the bigger issues and short covering, as in AGPH and IMNR today. CNTO, like AGPH, has always been a favorite of the shorts, both somewhat unjustifiably in my opinion.

I continue to hold my smallish long position, mostly because I believe the ReoPro/Retavase combination is going to prove a winner.

Peter



To: JohnP who wrote (783)10/30/1998 9:47:00 PM
From: Alfredo Nova  Read Replies (2) | Respond to of 965
 
To all:
bought a lot of Centocor at 37. Will hold after comments of robust Reopro sales, good potential for Remicade and especially pipeline monoclonal antibodies to Interleukin 6 and 12.
I think Remicade will be good for rheumatoid arthritis. Saw an article done in England with very good data.
Alfredo


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News